On Monday we learnt from Sir Patrick Vallance, the government’s Chief Scientific Adviser that Coronavirus will most likely by no means disappear and a vaccine will not cease it fully. He also said that ministers and authorities ought to quit ‘over-promising’ and be realistic about the prospects of a vaccine and the most likely timeline of one, unlikely prior to spring next year.
He then echoed his earlier warnings and these of his colleague Professor Chris Whitty that the COVID-19 fight will be a long one particular, and it will be with us for good.
So, from this must we assume there is no ‘silver bullet’ for COVID-19 infections?
What if there were a single remedy that:
could quit the infection in its tracks,
was anti-inflammatory controlling the immune system’s response to the infection and stopping it from overreacting dangerously,
in situations where individuals created secondary bacterial infections in the lungs could supercharge antibiotics boosting their efficacy and eve,
was a repurposed drug already proven as safe
was simple to make, scalable at the level necessary to make a distinction in the pandemic and was cost productive, then wouldn’t that be anything we really should all be getting excited about?
Surely although no such ‘silver bullet’ game changing therapy exists? After all, the only treatment options we hear about for COVID are these which President Trump took, which were either extremely new, highly-priced and experimental or have a quite narrow application to a certain aspect of the illness.
Properly, you heard it right here 1st – such a ‘silver bullet’ therapy does exist nowadays. It’s named Nylexa®, from the smaller UK biotech company NovaBiotics Ltd. It’s active components have been safely applied in medicines that treat unrelated circumstances for more than 30 years.
NovaBiotics discovered Nylexa’s prospective benefits in COVID-19 following a decade of analysis in difficult to treat, drug-resistant infections, like the complicated chest infections and inflammation associated with cystic fibrosis (CF) lung illness. In March they applied for a £1m grant from Innovate UK (representing the government) to start off clinical studies. That grant was sooner or later awarded earlier this month, and the government are now thinking about whether or not or not to include Nylexa on two separate NHS platform research.
But why, I hear you ask, if this is so very good have we not heard about it just before? Why are the government and the press not shouting about this from the rooftops? Why is this not being demanded by clinicians desperate for efficient therapies for their patients?
I’m afraid to say, it all boils down to cash. Little biotech firms obtain it difficult to get interest as they never have the sources out there to their larger superior funded rivals. The names we study about consistently when it comes to ground breaking new remedies are invariably significant multi-national pharmaceutical corporations with deep pockets and significant budgets to market their personal certain wares. They make confident their drugs get the expected interest. NovaBiotics is a compact private business funded by a group of loyal and supportive shareholders so unfortunately do not have the sources to compete for interest with the huge boys.
Which is why Center For Covid Control is so frustrating. In mitigating the overall health consequences of contracting COVID-19, Nylexa® could enhance public self-assurance of living with the virus for the longer term and potentially let a greater degree of normality to return to the way in which we reside, benefiting the economy straight in addition to easing COVID-19’s burden on the NHS and healthcare systems globally. But finding people in positions of influence to take notice amongst all the other folks competing for their interest is pretty tough certainly.
It is reported that there are thousands of possible COVID-19 treatment options in clinical trials across the globe. I would challenge any individual to show me a single which has the identical potential for good impact as Nylexa®, yet this is not at present aspect of any trial, despite its impeccable credentials. So come on UK Government, and ministers, get your finger out and get this drug into trials immediately. The sooner it gets tested, the sooner it can be utilized to aid sort out the mess the pandemic has caused to all our lives.
About NovaBiotics Ltd
NovaBiotics Ltd is a clinical-stage biotechnology corporation focused on the design and improvement of initially-in-class therapies for difficult-to-treat, medically unmet infectiousdiseases brought on by bacteria and fungi and respiratory situations including cystic fibrosis and COVID-19.
A major innovator in the anti-infectives space, the Company’s robust technology and small business model has been validated by way of profitable improvement, from idea to late stage clinical improvement, of its most advanced solution candidates. In addition to the lead Nylexa® programme and the Company’s other late-stage assets (Lynovex® for cystic fibrosis, NP213/Novexatin® for onychomycosis), NovaBiotics has generated a robust pipeline of earlier stage, high-worth drug candidates which includes NP339 (Department of Health and Social Care funded programme) for life threatening, drug resistant invasive fungal illness and NP432 for multi- drug resistant bacterial infections.